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Abstract
Micro-RNAs (miRNAs) are small non-coding RNAs that regulate gene products at the post-transcriptional level. It is thought
that loss of cell regulation by miRNAs supports cancer development. Based on whole genome sequencing of a melanoma
tumor, we predict, using three different computational algorithms, that the melanoma somatic mutations globally reduce
binding of miRNAs to the mutated 39UTRs. This phenomenon reflects the nature of the characteristic UV-induced mutation,
C-to-T. Furthermore, we show that seed regions are enriched with Guanine, thus rendering miRNAs prone to reduced
binding to UV-mutated 39UTRs. Accordingly, mutation patterns in non UV-induced malignancies e.g. lung cancer and
leukemia do not yield similar predictions. It is suggested that UV-induced disruption of miRNA-mediated gene regulation
plays a carcinogenic role. Remarkably, dark-skinned populations have significantly higher GC content in 39UTR SNPs than
light-skinned populations, which implies on evolutionary pressure to preserve regulation by trans-acting oligonucleotides
under conditions with excess UV radiation.
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Introduction
Melanoma is one of the main life-threatening malignancies of
our era, accounting for 75% of skin cancer–related deaths world-
wide [1]. Transformation and development of metastasis require
stepwise acquisition of genetic and functional alterations [2,3].
The roles of epigenetic and post-transcriptional mechanisms in
melanoma are in the focus of recent studies [4,5].
miRNAs are small, non-coding, 19–22 nucleotide long RNA
strands, which function as specific epigenetic regulators of gene
expression by inhibiting protein translation, leading mRNA to
degradation, or both [6,7]. The ‘‘seed’’ region, located between
nucleotides 2 to 8 of the mature miRNA, binds to complementary
regions in the 39 un-translated region (39UTR) of target mRNA to
direct post-transcriptional repression. To date, nearly 1000 human
miRNAs have been identified [8], and those are thought to regulate
more than 50% of human genes [9]. Not surprisingly, their
expression pattern isfrequentlyperturbedindevelopmental diseases
and cancer, which can directly exert phenotypic effects [10,11,12,
13,14,15]. In melanoma, several studies pointed on individual
miRNAs whose expression level is likely to be related to formation
and development of the cancer [16,17,18] or to the aggressive
phenotype of melanoma cells [19]. Exemplar miRNAs include the
inhibitory miRNAs miR-34a [19], miR-193b [20], let-7a [21], and
miR-211 [22,23], while miR-182 [24] and miR-221/222 [22] were
shown to stimulate metastatic potential of melanoma cells.
Over recent years it was suggested that miRNAs are globally
down regulated in human cancers [7]. Supporting this claim, it
was shown that impaired processing of miRNAs promotes cellular
transformation and tumorogenesis [25]. This trend was demon-
strated in lung-cancer [26] and melanoma lymph node metastasis
[16], in which more miRNAs were down-regulated than up-
regulated. Cancer cells also exhibit frequent genomic alterations in
regions of miRNA genes, reflected mainly as copy number
variations [27]. These alterations are highly specific to the cancer
type. In melanoma, 86% of the 283 examined miRNAs exhibited
copy number variations, more than any other tested cancer, with
198 gains and 235 losses. Among those, 83 gains and 160 losses
were specific to melanoma and explicitly associated with tran-
scriptional expression, meaning that the overall activity of mi-
RNAs is expected to be reduced in melanoma [27]. Noteworthy,
this general trend may be cancer-specific, as global up-regulation
of miRNA expression was observed in other solid malignancies
[15,28]. Current research therefore focuses on exploring differen-
tially expressed miRNAs in cancer cells versus their normal coun-
terparts and to relate these changes to cancer development and
progression. There is still, however, a major gap in the under-
standing of how somatic alterations affect global cell regulation by
expressed miRNAs, for example by altering their binding sites.
Recent studies employed enhanced sequencing technologies to
obtain complete maps of genomic variants detected in tumors
and compare them to normal tissues. These studies detected
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rearrangements in breast cancer [30], somatic mutations in a small
cell lung cancer [31], acute myeloid leukemia (AML) [32,33] and
mesothelioma [34]. Typically, 20,000–30,000 genomic somatic
mutations were found in each tumor genome, including hundreds
within known genes, of which almost half within UTRs. It is still
very difficult to identify the minority of mutations responsible
directly to cancer formation (‘‘driver’’ mutations). These studies
emphasized that different cancers are characterized by different
types of DNA aberrations, which are related to the mutagenic
process. In melanoma, typical UV-induced single base substitu-
tions account to more than 80% of all substitutions [31,35] and
primarily include C-to-T/A-to-G [36,37,38]. CC-to-TT is the
prominent dinucleotide substitution [31]. The unique composition
of UV-induced somatic mutations mandates examination of its
effect on global cellular processes, such as global miRNA binding.
Here we show using three different computational tools that the
UV-induced pattern of somatic mutations in melanoma reduces
the general binding of miRNAs to mutated 39UTRs. To the extent
of our knowledge, this is the first study to predict disruption of
miRNA-mediated regulation of gene expression due to a car-
cinogen. The implications of these observations are discussed,
especially in light of a striking difference identified in nucleotide
composition of SNP sites within the 39UTRs between light- and
dark-skinned populations.
Results
Mutations in the 39UTR found in melanoma globally
reduce miRNA binding
SNV analysis between melanoma cells and normal melanocytes
revealed a ,1:1 ratio between those found within coding
sequences and untranslated regions (UTRs) of known genes
[31]. We hypothesized that miRNA binding to the mutated UTRs
will be altered as compared to the normal UTRs.
All 207 point mutations discovered within 39UTRs of known
genes were analyzed by prediction tools for global miRNA binding
to the 39UTRs. Strikingly, Pita program [39] predicted a highly
significant global miRNA binding preference to the reference
genomic sequence over the mutated sequence (p=2.5610
26)i n
the melanoma patient genome, independently of the exact DDG
threshold chosen to define binding (Figure 1A). These results
were further ratified (p=0.0057) with a second prediction tool,
miRanda, also under a wide range of DDG threshold values
(Figure 1B). Moreover, Mirhb, an in-house code to detect target
sites for miRNAs based on defined number of satisfied hydrogen
bonds, showed the same phenomenon (p=0.0046) over a wide
range of number of hydrogen bond satisfaction (Figure 1C).
Importantly, similar results with all three miRNA target prediction
programs were also obtained (p=0.0028, 0.035, 0.033 with pita,
miRanda and Mirhb respectively) upon re-calculation for a
selected set of 167 miRNAs, which was defined as ‘‘Melanoma
miRNA set’’ by Caramuta et al [16] (Figure 1, D–F).
This phenomenon is exemplified here for two private cases:
PAX7, a homeodomain transcription factor that plays important
roles during fetal development and cancer growth [40] (Figure 1G),
and KITLG, a ligand of the KIT tyrosine-kinase receptor, which
acts in cellular development [41] (Figure 1H). Overexpression of
both genes has been implicated in melanoma [42,43] and both
received high scores by the prediction programs, with PAX7 ranked
first according to consensus prediction of the three algorithms
(Table S1). These examples well represent the general trend, in
which putative miRNA binding sites covering the somatic mutation
sites tend to vanish due to the mutations rather than be created.
Global reduction in miRNA binding is specific to
melanoma as a consequence of the typical UV-induced
mutations
The effect of mutations in the 39UTRs on global miRNA
binding in melanoma was compared to two other recently pu-
blished complete cancer genomes, small cell lung cancer [31] and
AML [32]. According to all three programs, the percentage of
genes with predicted reduced miRNA binding due to the mu-
tations was significantly larger in melanoma as compared to the
other malignancies (Figure 2A). This general trend was observed
over a wide range of any chosen parameter applied to define
miRNA binding (Figure 2A). It is implied, therefore, that global
reduction in miRNA binding is characteristic of melanoma.
Indeed, an SNV-based analysis of the types of nucleotide sub-
stitutions verified that the melanoma set of mutations is unique by
a very high frequency of C-to-T/G-to-A transitions (64.5% of all
substitutions, Figure 2B left column), which are known to be
induced by UV radiation [31,36,37,38]. The second most com-
mon substitution in 39UTR was found to be C-to-A/G-to-T, in
agreement with the mutation frequencies for the entire genome
[31]. Taken together, the two leading types of mutations in
melanoma are of type Strong-to-Weak in terms of thermodynamic
hybridization stability. Moreover, the melanoma mutation profile
is dramatically skewed, as 75% of all substitutions are of Strong-to-
Weak, while the reciprocal Weak-to-Strong substitutions account
for only 13.9% (Figure 2B, right column). The mutation profiles of
lung cancer or AML were more balanced, with 47–48% of Strong-
to-Weak and ,32% of Weak-to-Strong substitutions (Figure 2B,
right column). Such mutations are expected to reduce the
thermodynamic stability of any cis- or trans-hybridizations.
The reduced global binding in melanoma was next studied with
Miranda in random sets of point mutations in the same 39UTRs,
in order to determine whether it is restricted to the mutation sites
or results from the characteristic melanoma mutation profile type
(Figure 3A). There was clearly no reduced binding in two sets, in
which the position of the mutation and its type were both ran-
domly chosen. To examine the importance of the type of sub-
stitution we constructed a set with in silico mutations of the same
type as the originally observed mutations in randomly located
sites along the 39UTR (‘‘same type set’’). Remarkably, this set
demonstrated similar overall results to the original set of the real
mutations, confirming that the type of substitutions accounts for
the reduced miRNA binding, with little or no contribution to their
exact location. A third random set of which the position of the
mutation was preserved but the type was randomly changed
(‘‘same position set’’) demonstrated an intermediate effect
(Figure 3A). It should be mentioned that due to the composition
of somatic mutations in melanoma this set is biased in its com-
position, which could explain the intermediate effect. Equivalent
analysis for the other cancers, such as lung cancer (Figure 3B) or
AML (Figure 3C) reveals less apparent differences in global
miRNA binding between the real mutated sequences and the sets
with different types of in silico mutations, as described above. This
observation is consistent with the hypothesis that the unique biased
composition of melanoma somatic mutations accounts for the
reduced miRNA binding phenomenon.
We noticed that there is a clear enrichment (p,10
-16)i nG C
content (mainly G) in the nucleotide composition of miRNAs
(49.3%) and within the seed regions (50.9%), as compared to the
GC content of the 39UTRs (42.4%) (Figure S1). This supports the
notion on the importance of the thermodynamic advantage of GC
pairs in miRNA binding. We used Mirhb to verify that the weaker
binding of miRNAs to 39UTRs is due to the special composition of
mutations and not due to modifications of entire sequence motifs.
Reduced miRNAs Binding in Melanoma
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GC pairs contribute equally to the binding as AT pairs. Im-
portantly, following this modification we obtained completely
different results, with more genes now showing preferred miRNA
binding to the mutated sequences (Figure 3D). Taken together, the
significant role played by GC pairs in miRNA binding and their
relative abundance within miRNAs and their seed regions,
suggests that the GC nucleotides in the 39UTRs have a greater
contribution for overall miRNA binding, despite their scarcity
compared to AT (Figure S1). Moreover, as the G content in
miRNAs and seed regions is higher by ,20% than the C content
(Figure S1), it is logical to assume that the complementary C
nucleotides in the 39UTRs have thus a greater overall significance
than G nucleotides. These observations are in perfect agreement
with results demonstrating that global miRNA binding is disrupted
only by the melanoma mutations (Figure 2A), which commonly
target C nucleotides (Figure 2B). There were no significant
differences in GC content in the 39UTRs of melanoma, AML and
lung cancer mutated genes (Figure S1), which further supports the
role of mutation type and not the specific local sequence context in
controlling miRNA binding.
It is of interest to characterize the type of miRNAs most affected
by the melanoma mutations, as this could shed further light on the
underlying molecular mechanisms. We therefore sortedall miRNAs
according to their differential binding to the mutated 39UTRs, by a
consensus prediction using the sum of the ranks for each program
separately (Figure 4 and Table S2). Literature review revealed
enrichment for down-regulated or tumor-suppressive properties
among the top 20 miRNAs in the list (most reduced binding). Re-
view of the bottom 20 miRNAs in the list (most enhanced binding)
revealed enrichment for up-regulation or oncogenic properties
(Table S2). Remarkably, target analysis with bioinformatics tools
Toppgene [44] and miRror [45] of the top 20 miRNA highlighted
biological processescontributingtooncogenicpropertiessuchascell
Figure 1. Global changes in miRNA binding due to 39UTR mutations in melanoma and illustrative examples. The upper part of subplots
A–F depicts the numbers of genes predicted to have more miRNA binding sites in the wild type sequence. The lower part of the subplots depicts the
total numbers of genes predicted to have more miRNA binding sites in mutated version of the genes. Each program was applied several times using
different threshold for miRNA binding (x-axis). A. Results according to pita [39] (x-axis units are DDG threshold to define miRNA binding in each run).
B. Results according to miRanda [54] (x-axis units are DDG threshold to define miRNA binding in each run). C. Results according to mirhb (x-axis units
are the numbers of satisfied hydrogen bonds in the seed region define miRNA binding in each run). D. Results according to pita but only based on
miRNAs expressed in melanoma [16]. E. Results according to miRanda only based on miRNAs expressed in melanoma. F. Results according to mirhb
only based on miRNAs expressed in melanoma. G. Changes in miRNA binding in paired-box 7 (PAX7) caused by melanoma somatic mutations. Red
color indicates a perfect base pairing whereas green color indicates wobble U:G base paring. In each example the upper panel shows all miRNAs
predicted by pita [39] to bind to the reference (wild type) sequence and the lower the miRNAs predicted to bind to mutated sequence along with
their respective predicted DDG binding free energy. H. Changes in miRNA binding in KIT ligand (KITLG).
doi:10.1371/journal.pone.0027400.g001
Reduced miRNAs Binding in Melanoma
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(Table S3). In marked contrast, target analysis of the bottom 20
miRNAs highlighted biological processes contributing to tumor
suppressive properties, such as apoptosisand regulation of cell death
(Table S3).
Decreased miRNA binding as a possible evolutionary
pressure
It is known that dark-skinned populations have a significantly
reduced risk to develop cutaneous melanoma [46]. While the
molecular explanation is not fully understood, it is thought to be
related to the more intense pigmentation, which protects against
UV radiation, the main melanoma-inducing carcinogen. However,
additional evolutionary adaptations that protect human populations
at geographical regions characterized by excess sunlight may exist.
We showed that the Strong-to-Weak mutations can potentially
affect miRNA binding (Figure 3) and thus potentially alter normal
regulation of the cell. We therefore speculated that significant
natural differences in nucleic acid compositions might distinguish
dark- and white-skinned populations. The GC (Strong) or AT
(Weak) composition of SNP sites in genotyping database of
Caucasians (Utah, originating from central Europe) and Sub-
Saharan Africans (Nigeria) available at the 1000 genomes project
[47,48] was analyzed and compared. In both populations, there was
clearly higher GC content over AT in SNP sites in the entire
genome (Figure 5A), with a particular high ratio in 39UTRs
(Figure 5B and Table 1). However, a remarkable and significant
difference (p,10
-16) in the GC/AT ratio was noted between the
two populations, with the ratio being greater in the Sub-Saharan
population compared to the central European population. To
exclude artifacts due to low coverage of SNP sites, we repeated the
analysis only with SNPs with greater coverage and obtained
essentially the same trend with even more apparent differences even
at more stringent coverage thresholds (Table 1). Similar results were
obtained when only compositions of SNPs reported in both
populations (Table 1) were considered. Collectively, these observa-
tions could suggest higher GC content due to selective pressure
against Strong-to-Weak mutations which may cause decreased
miRNAs binding, gene dysregulation and ultimately transforma-
tion. Moreover, it proves that the GC enrichment in polymorphic
sites happened in ancestral sites as well as in more recent sites
acquired after the migration of the Homo sapiens from Africa some
Figure 2. Global changes in miRNA binding due to 39UTR mutations in melanoma, lung cancer and AML and distribution of
mutation types. A. Shown are normalized differences between the total number of genes predicted to bind more miRNAs in the wild type
sequences and the total number of genes predicted to bind more miRNAs in the mutated sequence (Db over the total number of 39UTR mutated
genes) as predicted by the different programs. Each program was applied several times using different thresholds for miRNA binding (x-axis).
B. Distribution of mutation types in different cancer genomes [31,32,39]. The left pie charts show the row distribution of mutations while the right
charts show the distribution of mutations classified as Strong (S) or Weak (W) based on the number of hydrogen bonds in the base pairing (S=3,
W=2).
doi:10.1371/journal.pone.0027400.g002
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theSNPs that fall withinpredicted miRNAstarget sites. Strikingly,a
large and significant (p=10
-6) difference was observed between the
GC compositions of SNPs at target sites of miRNAs known to be
expressed in Melanoma and the GC content of SNPs falling at
target sites of other miRNAs (Table 1). The same trend was evident
for both populations but was more apparent among the Africans.
Discussion
Recent massive parallel cancer genomic sequencing studies are
expected to be the tip of the iceberg, considering the need to detect
specific functional genomic variants among tens of thousands of
differential SNVs distinguishing tumors from healthy tissues. The
,1:1 ratio between mutations in coding exons and UTRs [31]
highlighted the potential causative relevance of UTR mutations, such
as by altering miRNA binding sites.
UV radiation is the dominant mutagen involved in many cases
of melanoma-genesis. Therefore, melanoma cells are expected to
bear many Strong-to-Weak mutations due to the typical UV-
induced DNA damage. This was indeed evident in the first
complete genome of melanoma tumor [31] (Figure 2) and was
further corroborated by whole exome sequencing of 14 matched
normal and metastatic melanoma DNA samples [38]. Using
various miRNA target prediction programs applying conceptually
different algorithms, we show that these mutations are predicted to
reduce overall miRNAs binding to 39UTRs (Figure 1). The
reduced binding is melanoma-specific (Figure 2), as it is mainly a
consequence of the type of mutation rather than its exact position
(Figure 3). It is therefore expected to be a general phenomenon,
which would be valid for every set of mutations preserving the
mutation frequencies observed in melanoma. We are well aware
that miRNA target prediction level using today9s software may
still be inaccurate. Nevertheless, three different algorithms and
Figure 3. Global changes in miRNA binding due to 39UTR mutations vs.in silico mutations. A. Global changes in miRNA binding due to
39UTR mutations in real melanoma mutations compared to sets with random in-silico mutations. Shown are normalized differences between the
numbers of genes predicted to bind more miRNAs in the wild type sequences and the numbers of genes predicted to bind more miRNAs in the
mutated sequence (Db over number of 39UTR mutated genes). Predictions were made using miranda. See text for description of the different random
sets. B. Global changes in miRNA binding due to 39UTR mutations in small cell lung cancer mutations compared to sets with random in-silico
mutations. C. Global changes in miRNA binding due to 39UTR mutations in AML mutations compared to sets with random in-silico mutations.
D. Global changes in miRNA binding when GC base paring is thermodynamically favored (upper panel) and when artificially set to be equal to AU
pairing (lower panel). The upper part of each panel depicts the numbers of genes predicted to have more miRNA binding sites in the wild type
sequence. The lower part of each panel depicts the total numbers of genes predicted to have more miRNA binding sites in the mutated version of the
genes. This figure emphasizes that the preferred miRNA binding in the wild-type sequences over the mutants is not due to ruining of particular
sequence motifs, but due to the enhanced thermo stability of the CG base pairing.
doi:10.1371/journal.pone.0027400.g003
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are therefore carefully drawing the global conclusions, which sh-
ould not be biased or affected by incorrect prediction of particular
miRNAs binding sites.
Previous studies reported on down-regulation of miRNA expre-
ssion in several cancers [13] and that generic impairment in
miRNA processing promotes cellular transformation and tumor-
igenesis [25]. Transcripts in cancer cells also exhibit shorter
versions of 39UTR which may cause loss of miRNA-mediated
repression [49]. Our study is the first to address the function of
expressed miRNAs from the aspect of target gene binding. The
presented results imply that somatic mutations in melanoma
disrupt miRNA-mediated regulation of many genes, which is
consistent with the notions of reduced miRNA-mediated regula-
tion in cancer. The studies claim for global up regulation of
miRNAs in cancer [15,28], could reflect tissue specific physiology,
or in other cases an endogenous cellular compensation mechanism
for the reduced binding, in an attempt to maintain regulation of
gene expression. Here we attempted to analyze global functional
trends regulated by the affected microRNAs (Figure 4 and Tables
S2–3). miRNAs were ranked and clustered according to their
calculated ability to bind wild type or mutant sequences. It seems
that this ranking reflects some functional properties, however it
should be considered with cautious as it is based on a single
melanoma genome. Future sequencing of many whole melanoma
genomes will allow accurate evaluation of the types of most
affected miRNAs and their potential role in cancer development.
Usually, mutations detected in cancerous tissues are described as
‘‘passenger’’ or ‘‘driver’’ mutations, with the vast majority being
‘‘passengers’’ [37]. Random mutations may hit selected tumor
suppressors or oncogenes and could lead, in individual genes level, to
cancer formation and progression. Here we suggest a new intermediate
class of ‘‘dormant driver’’ mutations. Such mutations bear a modest
functional effect, such as reduction of few miRNA binding to their
target genes, which may not manifest phenotypically on the individual
gene level. On the system level, however, when accumulation of such
mutations in many genes reaches a critical point, a significant global
perturbation in expression pattern of many genes may shift the system
off-balance, severe cell dysregulation and potentially carcinogenesis
might ensue. This hypothesis is in line with recently published study
demonstrated the role of cryptic genetic variation in the evolution of
RNA enzymes [50]. Indeed, in many instances cancer development
cannot be fully explained based on combination of mutations in known
oncogenes and tumor suppressors.
UV is a mutagen, which is known to exert its carcinogenic effect by
introducing random ‘‘driver’’ and ‘‘passenger’’ mutations into coding
and regulatory elements of individual genes [31]. Generation of
‘‘dormant driver’’ mutations comprises a new, UV-specific, mecha-
nism of carcinogenesis. This UV-unique mechanism is probably
completely independent from the conventional mutagenic effects of
Figure 4. miRNAs sorted according to the difference between the number of 39UTR miRNA binding sites predicted in the wild type
sequences and the number of binding sites predicted in the mutated genes (Db). Zoom-in is given for the top 30 miRNAs at both ends of
the sorted list.
doi:10.1371/journal.pone.0027400.g004
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dependent on GC pairs (Figure 3), and the presumed greater con-
tribution of 3’UTR C nucleotides for miRNA binding, render the
miRNA-binding sites highly susceptible to UV mutagenesis, because
it causes mainly C-to-T mutations. Furthermore, it is expected to be
applicable also in other UV-facilitated non-melanoma malignancies,
such as squamous cell and basal cell carcinomas. This provides fur-
ther mechanistic explanation for the role of UV as a major cause for
the most common human malignancy, skin cancer [51].
Finally, we show that there is a surprising, highly significant,
difference in the GC/AU ratio in the 3’UTRs between dark- and light-
skinned human populations (Figure 5B). The importance of GC
nucleotides and their thermodynamic advantage in conferring
thermodynamic stability to DNA structures in response to UV-
induced damage was suggested previously [52]. Here we suggest a
novel role for GC nucleotides as facilitators of miRNA binding and
thereby global cell regulation. It is tempting to speculate that this might
be an evolutionary strategy to minimize UV radiation effects and
reduce risk for development of skin cancer. The observed differences in
GC content between SNPs falling within predicted target sites of
miRNAs highly expressed in melanoma and target sites of other
miRNAs strongly supports this speculation. The context or role of this
observation in differential melanoma morbidity rates between dark-
and light-skinned human populations remains to be elucidated.
Materials and Methods
Datasets of cancer mutations
Datasets of SNVs obtained using massively parallel genomic
sequencing of cancer patients were obtained for melanoma [31],
small cell lung cancer [31] and AML [32]. The first two sets were
obtained from the supplementary materials of the publications.
The complete list of the AML mutations was obtained from
dbGAP of NCBI [53]. The datasets and the reference coordinates
were based on version NCBI36 (HG18) of the human genome.
MiRNA target predictions
Pita [39] and Miranda [54] were applied for prediction of
miRNA targets. Miranda uses complementary sequence informa-
Figure 5. Base frequencies at SNP sites among Utah residents having European ancestry (CEU) and among Yoruba people from
Nigeria, Africa (YRI). SNP frequencies were calculated based on the 1000 genomes project data. A. Whole genome SNPs analysis B. 39UTR SNPs
analysis.
doi:10.1371/journal.pone.0027400.g005
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cessibility of the target molecules to trans-acting factors which
improved prediction accuracy. We ran each of the programs using
different DDG thresholds to define miRNA binding.
For global analysis of miRNA binding we defined Db as the
number of genes with more miRNAs bound to the wild type
sequence minus number of genes with more miRNAs bound to the
mutated sequence.
For global analysis of miRNA targets and their overlap with
SNP sites we used pre-calculated Pita targets available in the web
site: (http://genie.weizmann.ac.il/pubs/mir07/mir07_data.html)
Mirhb - target prediction program based on satisfied
hydrogen bonds
A new in-house tool for miRNA target prediction, Mirhb, has
been applied. Mirhb searches for miRNA targets according to the
number of satisfied hydrogen bonds rather then percent identity or
number of base mismatches. Due to its simple scoring scheme the
program is extremely fast and can be used to check binding of
many miRNAs vs. many UTRs, a utility not provided by most
existing miRNA target prediction programs. The mirhb script,
written in Perl is available at http://sheba-cancer.org.il/software/
mirhb.
MiRNA database
We used version 9.09 (September 2009) of mirBase [55] which
holds 718 highly confident miRNAs.
Gene annotations
Annotations and coordinates of genes were taken from the
UCSC genome browser web site using the Table Browser tool
[48].
1000 genomes project data
Files with genotyping of 100 individuals of Utah residents with
Northern Western European ancestry (CEU) and of 100 in-
dividuals of the Yoruba in Ibadan, Nigeria (YRI) were down-
loaded from the pilot1 section in the 1000 genomes project site
(http://www.1000genomes.org/) [47,48]. These files list the
genotyping of all sequenced individuals in each SNP position
with supportive data on quality and coverage deepness.
MiRNA expression data in melanoma
GEO experiment GSE19387 which holds the data from the
work of Caramuta et al. [16] was used to define miRNAs changing
expression in melanoma.
We used data from Hoek et al. [56] (GEO GSE4570) to detect
genes which undergo expression change in melanoma cells.
Prediction of commonly regulated targets
For prediction of commonly regulated targets for selected set
of miRNAs, the mirror [45] algorithm was applied using p-
value,0.05 as threshold.
Prediction of biological processes
For prediction of biological processes Toppgene [44] algorithm
was applied with p-value,0.05 as threshold.
Statistical analysis
To compare GC content of entire UTRs and miRNA binding
regions and GC content at SNP sites between different po-
pulations, chi-square test was applied. To examine the significance
of the difference between genes having more miRNAs bound to
the reference sequence and those with more miRNAs bound to the
mutated sequences at different binging thresholds we used paired
t-test.
Table 1. Nucleotide frequency at SNP sites based on the 1000 genomes project.
YRI CEU p-value
#SNPs #SNP calls %GC %AT #SNPs #SNP calls %GC %AT
DP
1=5 genome 10546163 359168638 56.72 43.28 7722361 424769524 54.27 45.73 ,E-16
39UTR 162148 5782684 57.95 42.05 118338 6542524 55.51 44.49 ,E-16
Melanoma miRNA
targets
259 8472 56.95 43.05 187 10820 54.82 45.18 ,E-16
Other miRNA targets 1449 46080 51.41 48.59 1079 61934 51.09 48.81 0.3
DP=8 genome 9701436 91323858 58.02 41.98 7667681 153696724 54.32 45.58 ,E-16
39UTR 151938 1556216 59.11 40.89 117398 2434198 55.42 44.58 ,E-16
Melanoma miRNA
targets
241 2070 58.50 41.50 186 4006 55.47 44.53 ,E-16
Other miRNA targets 1287 10974 53.06 46.94 1076 23082 51.30 48.70 0.0032
DP=11 genome 5098112 18765018 59.29 40.71 6894889 49433786 54.43 45.57 ,E-16
39UTR 87210 344426 60.29 39.79 105966 818104 55.48 44.52 ,E-16
Melanoma miRNA
targets
103 358 60.34 39.66 171 1356 53.76 46.24 0.0977
Other miRNA targets 628 2238 55.41 44.59 987 7640 51.75 48.25 0.0023
Common
SNPs
2,D P=5
genome 4955571 165131624 54.61 45.39 4959997 273988408 52.84 47.16 ,E-16
39UTR 73131 2559830 55.57 44.43 73192 4061996 53.68 46.32 ,E-16
1. Minimal deepness of coverage for each site counted.
2. SNPs appear in both populations.
doi:10.1371/journal.pone.0027400.t001
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genes are sorted by consensus Db value calculated by the different
programs.
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RNAs binding. miRNAs were ranked according to their
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of the three prediction programs. Top ranked miRNAs are predicted
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